<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fas (Apo-1/CD95) ligand (FasL) is a cytotoxic molecule used by T lymphocytes and natural killer cells for target-cell killing and by nonmalignant and malignant cells in the suppression of immune responses </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, FasL expression in B- and T-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> was investigated by paraffin immunohistochemical analysis </plain></SENT>
<SENT sid="2" pm="."><plain>FasL expression was found to be weak in nonaggressive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, lymphoplasmacytoid <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, Grade 1 follicular center cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> but strong in aggressive B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, Burkitt's-<z:hpo ids='HP_0002665'>lymphoma</z:hpo>) </plain></SENT>
<SENT sid="3" pm="."><plain>Precursor B-lymphoblastic <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were more <z:hpo ids='HP_0001425'>heterogeneous</z:hpo>, with expression varying from weak to strong </plain></SENT>
<SENT sid="4" pm="."><plain>In T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (anaplastic large-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unspecified), strong FasL expression was observed </plain></SENT>
<SENT sid="5" pm="."><plain>Apparently, FasL expression is not limited to <z:hpo ids='HP_0002664'>neoplasms</z:hpo> derived from T cells or natural killer cells, and it might play a supporting role in the progression of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>